Promjena glikozilacije immunoglobulina G tijekom starenja by Krištić, Jasminka
 
 
 
 
 
FACULTY OF SCIENCE 
DEPARTMENT OF BIOLOGY 
 
 
 
 
 
Jasminka Krištić 
 
 
 
 
CHANGES OF IMMUNOGLOBULIN G 
GLYCOSYLATION WITH AGE 
 
 
DOCTORAL THESIS 
 
 
 
 
Zagreb, 2018. 
 
 
 
 
 
 
PRIRODOSLOVNO-MATEMATIČKI FAKULTET 
BIOLOŠKI ODSJEK 
 
 
 
 
 
Jasminka Krištić 
 
 
 
 
PROMJENA GLIKOZILACIJE 
IMMUNOGLOBULINA G TIJEKOM 
STARENJA 
 
 
DOKTORSKI RAD 
 
 
 
Zagreb, 2018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work presented in this doctoral thesis was performed at Genos Ltd., Zagreb, 
Croatia under the supervision of Prof. Gordan Lauc, PhD, as a part of the postgraduate 
doctoral programme in Biology at the Department of Biology, Faculty of Science, 
University of Zagreb.  
 
 
 
Ovaj je doktorski rad izrađen u Genos d.o.o., Zagreb, Hrvatska, pod vodstvom prof.  
dr. sc. Gordana Lauca, u sklopu Sveučilišnog poslijediplomskog doktorskog studija 
Biologije pri Biološkom odsjeku Prirodoslovno-matematičkog fakulteta Sveučilišta u 
Zagrebu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zahvale 
 
Najljepše se zahvaljujem svom mentoru prof. dr. sc. Gordanu Laucu koji mi je omogućio da se 
bavim znanošću te što nadahnjuje svojim idejama i entuzijazmom kojim priča o znanosti. 
  
Toplo se zahvaljujem cijeloj ekipi s posla na ugodnoj radnoj atmosferi i suradnji na brojnim 
projektima.  
Posebno hvala Tomi od kojeg sam puno naučila prvih mjeseci u Genosu.  
Hvala Maji što rado prenosi svoje veliko znanje iz glikobiologije te na brojnim savjetima i 
razumijevanju. 
Hvala Tomislavu na čitanju i lektoriranju doktorskog rada, te na lijepim manirama u 
ophođenju s drugima. 
Mirni, Dajani, Ivoni i Ireni hvala na prijateljstvu. 
 
Iako piše da zahvalu svedemo u akademske okvire, ne znam hoću li se ikada više imati prilike 
javno zahvaliti određenim osobama, pa ću zato to učiniti ovdje. 
Ne tako davno čula sam izreku „Iza svakog uspješnog muškarca stoji njegova žena, a iza svake 
uspješne žene njezina majka!“. Pa ako sam ja uspješna zato što ću imati doktorat znanosti, onda 
iza toga svakako stoji moja mama! Mama hvala ti na svemu, svom trudu, vremenu, savjetima, što 
si moj “glas savjesti“. Hvala tati što nas je uvijek poticao na više i bolje. Hvala mojoj sestri i 
bratu na podršci i ljubavi. 
Hvala mom suprugu Vinku koji mi je podrška u svemu što radim i koji o glikobiologiji zna puno 
više nego što bi jedan sveučilišni specijalist ekonomije trebao znati! Hvala mojim djevojčicama 
Tonki i Marini uz koje je sve istodobno i teže i lakše, ali sve ima više smisla! 
Hvala mojim dragim prijateljicama Zrinki, Nataši, Ivani i Mirti što me prate kroz život. 
 
Na kraju, zahvaljujem se dragom Bogu. „Znam da tvoja ruka životom mojim ravna i svaki korak 
tvoj mi pogled prati.“ 
 
 
 
 
 
 
 
 
 
 
 
University of Zagreb        Doctoral thesis 
Faculty of Science 
Department of Biology 
 
 
CHANGES OF IMMUNOGLOBULIN G GLYCOSYLATION WITH AGE 
 
JASMINKA KRIŠTIĆ 
Genos Ltd. 
BIOCentar, Borongajska cesta 83h, Zagreb, Croatia 
 
In this thesis, glycosylation of immunoglobulin G (IgG) was examined in 5818 individuals 
ranging in age from 16 to 100 years from five different populations – four European populations 
and a Han Chinese population by using ultra performance liquid chromatography (UPLC) in 
order to provide a comprehensive overview of changes in IgG glycosylation through lifetime. The 
results demonstrated that glycan profiles change in a similar way through lifetime across all 
examined populations. Nearly all IgG glycans were significantly associated with age. Sex 
differences in age-related changes in IgG glycosylation were observed. The combination of 
several IgG glycans was able to explain from 30 to 58% of variance in chronological age, with 
the remaining variance in the glycans attributed to physiological parameters. Analysis of IgG 
glycosylation in nearly 600 mice from the Collaborative Cross cohort ranging in age from 20 to 
80 weeks showed that, generally, only the level of IgG glycan with alpha-1,3-galactose changed 
with age. 
(84 pages, 10 figures, 9 tables, 226 references, original in English) 
 
Keywords: glycosylation, immunoglobulin G, chronological age, biological age, biomarker, 
humans, mice 
 
Supervisor: Professor Gordan Lauc, PhD 
Reviewers: Associate professor Olga Gornik, PhD 
        Professor Kristian Vlahoviček, PhD 
        Professor Igor Rudan, PhD 
  
 
 
Sveučilište u Zagrebu        Doktorski rad 
Prirodoslovno-matematički fakultet 
Biološki odsjek 
 
 
PROMJENA GLIKOZILACIJE IMUNOGLOBULINA G TIJEKOM STARENJA 
 
JASMINKA KRIŠTIĆ 
Genos d.o.o. 
BIOCentar, Borongajska cesta 83h, Zagreb, Hrvatska 
 
U ovom doktorskom radu analizirana je glikozilacija imunoglobulina G (IgG) kod 5818 osoba 
starosti od 16 do 100 godina iz pet različitih populacija – četiri europske populacije i populacije 
Han Kineza, koristeći tekućinsku kromatografiju vrlo visoke djelotvornosti (UPLC), kako bi se 
pružio detaljan pregled promjena u glikozilaciji IgG-a tijekom starenja. Rezultati su pokazali da 
se glikanski profili tijekom starenja mijenjaju na sličan način u svim istraživanim populacijama. 
Gotovo svi IgG glikani pokazali su se povezanima s dobi. Uočene su razlike između spolova u 
promjenama koje se događaju s glikozilacijom IgG-a tijekom starenja. Kombinacijom nekoliko 
IgG glikana bilo je moguće objasniti od 30 do 58% varijacije u kronološkoj dobi, a ostatak 
varijacije u glikanima pripisan je fiziološkim parametrima. Analiza glikozilacije IgG-a kod 
gotovo 600 miševa starosti od 20 do 80 tjedana iz Collaborative Cross populacije miševa 
pokazala je da se, sveobuhvatno gledajući, samo razina IgG glikana koji sadrži alfa-1,3 vezanu 
galaktozu promijenila s dobi. 
(84 stranice, 10 slika, 9 tablica, 226 literaturnih navoda, jeziki izvornika: hrvatski) 
 
Ključne riječi: glikozilacija, imunoglobulin G, kronološka dob, biološka dob, biomarker, 
ljudi, miševi 
 
Mentor: Prof. dr. sc. Gordan Lauc 
Ocjenjivači: Izv. prof. dr. sc. Olga Gornik 
          Prof. dr. sc. Kristian Vlahoviček 
          Prof. dr. sc. Igor Rudan 
  
 
 
TABLE OF CONTENTS 
 
1. INTRODUCTION ……………………………………………………………………......  1 
1.1 A general overview of protein glycosylation ……………………………………...  2 
1.2 Immunoglobulin G glycosylation ……………………………………………….....   2 
1.3 The impact of glycosylation on the structure and biological function of IgG ….….   5 
1.4 Changes in IgG glycosylation have been observed in many diseases ……………..  8 
1.5 Aging ………………………………………………………………………………  8 
1.6 Chronological and biological age ……………………………………………….. .. 9 
1.7 Biomarkers of aging ………………………………………………………….......  10 
1.7.1 Telomere length …………………………………………………………..  10 
1.7.2 DNA methylation …………………………………………………………  11 
1.8 Aging in mice …………………………………………………………………….  12 
1.9 Changes in IgG glycosylation with age: Studies in human populations ………….  13 
1.10 Changes in IgG glycosylation with age: Studies in mice …………………………  18 
1.11 Research problem and scope of the thesis ………………………………………..  19 
2. Glycans are a novel biomarker of chronological and biological ages …………………..  20 
3. Profiling IgG N-glycans as potential biomarker of chronological and biological ages …  32 
4. Profiling and genetic control of the murine immunoglobulin G glycome ……………… 43 
5. GENERAL DISCUSSION ……………………………………………………………. . 55 
6. CONCLUSIONS ……………………………………………………………………….  61 
7. REFERENCE LIST …………………………………………………………………….  63 
8. APPENDICES ………………………………………………………………………….  79 
9. CURRICULUM VITAE ………………………………………………………………...  82 
 
Jasminka Krištić - Changes of immunoglobulin G glycosylation with age 
 
1 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
  
Jasminka Krištić - Changes of immunoglobulin G glycosylation with age 
 
2 
 
1.1 A general overview of protein glycosylation 
Glycosylation is one of the most common posttranslational modifications of proteins, through 
which complex sugar molecules (glycans) are covalently attached to proteins. In 1991 Apweiler 
et al.1 estimated that more than half of all proteins are glycosylated, however, according to more 
recent estimates, less than one-fifth of proteins appear to be glycosylated2. Despite that, this new 
study on the frequency of different types of posttranslational modifications also showed that 
glycosylation is among the top three most common posttranslational modifications of proteins. 
Glycosylation greatly affects the physical properties of proteins (e.g. solubility, conformation, 
folding, stability, etc.) as well as biological functions of proteins3. Therefore, glycans as an 
essential part of many proteins have an important role in almost all physiological processes 
including protein folding and trafficking, cell adhesion, cell signalling, proliferation, 
differentiation, cell migration, cell survival, development and immunity4. Changes in 
glycosylation have been reported in various diseasesnumerous references, including5–8 and it has also been 
shown that glycans have great potential as diagnostic and prognostic biomarkers of different 
diseases9–11. For that reason, there are a growing number of studies which try to link changes in 
glycosylation of a certain protein (or group of proteins) with a certain disease and/or phenotype in 
order to find new potential diagnostic and prognostic biomarkers for certain diseases or 
conditions and to get a deeper insight into the mechanism of a specific disease itself. One of the 
proteins whose glycosylation has been the subject of many such studies is immunoglobulin G 
(IgG).  One of the main reasons for this is the fact that IgG is the most abundant glycoprotein and 
the second most abundant protein in human plasma (albumin is the most abundant protein in 
human plasma, but it is not glycosylated)12. Therefore, IgG has a prerequisite to be a very good 
non-invasive biomarker. 
 
1.2 Immunoglobulin G glycosylation 
IgG antibodies are a very important component of the immune system as they protect the 
organism against invading pathogens. They are produced by B lymphocytes. The IgG antibody 
consists of two fragments - Fab and Fc (Figure 1). The Fab fragment (antigen binding fragment) 
is the part of the IgG molecule which specifically recognizes and binds different antigens like 
bacteria or viruses. The Fc fragment (crystallisable fragment) provides the effector function, 
which means that this fragment determines how the immune system responds or reacts to the 
presence of a specific antigen. Through the interaction of the IgG Fc fragment with activating or 
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inhibitory Fc gamma receptors (FcγR), which are expressed on the majority of innate immune 
effector cells such as mast cells, monocytes, macrophages, natural killer cells, neutrophils, 
eosinophils and dendritic cells, pro-inflammatory or anti-inflammatory effector pathways can be 
activated13,14. Furthermore, the Fc fragment of IgG can also interact with component complement 
C1q13 and activate the complement pathway with pro-inflammatory effects14. The Fc fragment of 
IgG is also involved in binding of IgG to the neonatal Fc receptor (FcRn) expressed on 
endothelial cells and monocytes15. The interaction of IgG with FcRn determines antibody half-life 
but is also potentially involved in the anti-inflammatory activity of IgG14,15. It is also known that 
the ability of IgG to interact with different Fc receptors or to activate complement varies 
depending on the IgG subclass14,16,17. In humans there are four different IgG subclasses, IgG1, 
IgG2, IgG3 and IgG4, which differ in the constant regions of their heavy chains and are named 
according to their relative abundance in plasma. In mice there are five different IgG subclasses: 
IgG1, IgG2a, IgG2b, IgG2c and IgG3, however, although similar in name, they are not direct 
homologues of the human proteins18,19. 
 
Figure 1. Schematic representation of immunoglobulin G (IgG). IgG protein is composed of 
two heavy and two light chains. IgG protein can also be devided into two functional fragments: 
antigen-binding fragment (Fab) which binds antigen and crystallizable fragment (Fc) which is 
important for effector functions such as ADCC or complement activation. Each heavy chain of Fc 
fragment contains a covalently attached N-glycan to highly conserved N-glycosylation site 
located at position aparagine (Asn) 297. In addition, some IgG molecules can contain N-glycans 
in the Fab fragment (~20% of IgG molecules). 
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IgG contains a conserved N-glycosylation site at position asparagine (Asn) 297 on each heavy 
chain of the Fc fragment. In addition, around 20% of IgGs also have additional glycosylation sites 
in the Fab fragment20–24. All IgG glycans have a pentasaccharide core structure (consisting of two 
N-acetylglucosamines (GlcNAc) and three mannose residues) which can be additionally modified 
with a core fucose, a bisecting GlcNAc, one or two galactoses and one or two sialic acids (Figure 
2). 
 
Figure 2. The composition of IgG glycans. 
More than 30 different glycan structures can be found on human IgG25. Overall, human IgG 
glycans are predominately biantennary structures and most of them are core-fucosylated (>90%). 
A bisecting GlcNAc is present in ~18% of human IgG glycans and sialic acid is found in ~25% of 
IgG glycans. Approximately 30% of human IgG glycans contain no galactose25. The largest and 
most complex IgG glycan structure is a core-fucosylated bianntenary glycan with two galactoses, 
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two sialic acids and with bisecting GlcNAc25. Furthermore, it is known that the Fab and Fc 
fragment are differentially glycosylated. In comparison to Fc glycans, IgG Fab glycans are 
generally more highly galactosylated, sialylated and have higher level of bisecting GlcNAc. On 
the other hand, Fc IgG glycans are more highly core-fucosylated than IgG Fab glycans and are 
mostly nonsialylated (neutral) structures20,26–28. 
Contrary to the protein part of the IgG molecule, the synthesis of the glycan part is not regulated 
by a template. Rather, glycans are synthesised by the concerted action of many different proteins, 
including glycosyltransferases, glycosidases, nucleotide sugar transporters, transcription factors, 
and many other proteins29. Additionally, the biosynthesis of glycans is influenced by various 
environmental factors and physiological conditions29–32. Despite the absence of a direct genetic 
template, a relatively high heritability of IgG glycosylation has been reported, ranging from 30% 
to 80%, depending on the IgG glycan25,33. 
While human IgG glycosylation has been well studied, data on IgG glycosylation in mice are 
rather scarce and obscure. The data available in the literature show that though most glycan 
structures found on mouse IgG are shared between human and mouse, IgG glycosylation in mice 
exhibits some different characteristics from those observed in humans. Mouse and human IgG 
glycosylation differs with respect to the type of sialic acid present at the terminus of sugar chains 
attached to IgG proteins; mouse IgGs contain sugars which terminate with N-glycolylneuraminic 
(Neu5Gc) acid while human IgGs have terminal N-acetylneuraminic acid  (Neu5Ac)34–36. Further, 
glycan structures with terminal alpha 1–3 bound galactose are found on mouse IgG but not on 
human IgG34. Also, several inconsistencies are found within the literature with regards to some 
specific features of mouse IgG glycosylation. Some studies reported that the level of fucosylation 
was higher for mouse than for human IgG and that almost all mouse IgG glycans contained core 
fucose35–37, while others reported that fucosylation of mouse IgG was lower than in humans38. 
Further, the prevailing view in the field is that mouse IgG does not have bisecting GlcNAc34–37. 
However, more recent evidence suggests that mouse IgG glycans may contain bisecting 
GlcNAc38,39. 
 
1.3 The impact of glycosylation on the structure and biological function of IgG 
It is well documented that IgG Fc glycosylation stabilizes the structure of the Fc fragment, which 
is required for binding to the Fc receptors and complement factors. Deglycosylation (i.e. the 
removal of glycans) of the Fc fragment results in decreased binding or complete loss of binding to 
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FcγR or to proteins involved in the complement pathways and thus leads to an inability of IgG to 
elicit effector functions including complement activation, antibody-dependent cellular 
phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC)40–43. It is also well 
known that differences in the Fc glycosylation pattern alter the conformation of the Fc fragment 
which in turn modulates the binding affinities of IgG for FcγR and complement factors enabling 
fine-tuning of the IgG Fc-mediated immune response42,44. 
Core fucose 
For example, the absence of core fucose on IgG glycans results in a stronger binding affinity of 
IgG to Fc gamma receptor IIIa (up to 50-fold increased binding) and leads to enhanced ADCC 
activity while the presence of core fucose reduces the ADCC activity of IgG45,46. Moreover, it 
was found that interactions between IgG Fc glycans and glycans of the FcγRIIIa receptor have an 
effect on binding affinity between IgG and FcγRIIIa where the presence of core fucose on 
glycans attached to Fc fragment sterically inhibited such interactions which resulted in decreased 
binding affinity for the receptor47. 
Bisecting GlcNAc 
The addition of bisecting GlcNAc to IgG glycans was reported to cause an increase in ADCC 
through higher affinity for FcγRIIIa48. However, Shinkawa et al49 showed that the presence of 
very high levels of IgG glycans with bisecting GlcNAc resulted in only a slight increase of 
ADCC activity and that high content of glycans lacking core fucose was more potent in 
enhancing ADCC when compared to bisected glycans. It is also known that the presence of 
bisecting GlcNAc inhibits the addition of core fucose50. 
Sialic acid 
The effector function of IgG can also be modulated by terminal sialic acid residues. Many studies 
have demonstrated that sialylation acts as a switch between pro-inflammatory and anti-
inflammatory activity of IgG51,52 (reviewed in53–55). IgG antibodies which are not sialylated 
stimulate pro-inflammatory immune responses through interaction with Fcγ receptors42. On the 
other hand, IgGs which contain sialylated glycans exhibit anti-inflammatory properties. 
Moreover, several lines of evidence suggest that sialic acid residues of  N-glycans attached to the 
IgG Fc fragment are responsible for the anti-inflammatory properties of intravenous 
immunoglobulin (IVIG) preparation but the exact mechanism by which sialylated IgGs exert anti-
inflammatory activity is still unclear14,42,44,51–56. One of the proposed mechanisms suggests that 
sialylated IgGs interact with the C-type lectin receptor DC-SIGN which increases expression of 
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inhibitory receptor FcγRIIb and thus suppresses inflammation57–59. However, conflicting results 
exist regarding the involvement of DC-SIGN in the anti-inflammatory activity of sialylated IgG 
and some other receptors which could recognize sialic acid and trigger anti-inflammatory 
pathways have been proposed53. Moreover, there is also some evidence that sialic acid can act in 
a receptor-independent manner to activate the anti-inflammatory response and that IVIG may 
recruit sialic acid-independent anti-inflammatory pathways44,53,54. 
Galactose 
Karsten et al60 have recently showed that galactosylated IgG also exerts anti-inflammatory 
activity by FcγIIB receptor- and Dectin-1-mediated inhibition of the complement pathway. On 
the contrary, IgG glycans which lack terminal galactose residues (agalactosylated glycans) posses 
the ability to interact with mannose binding lectin (MBL) and activate the lectin complement 
pathway61, and it has been shown that the pro-inflammatory activity of agalactosylated IgG is 
dependent on the presence of activating Fc receptors62. In addition, several lines of studies have 
demonstrated that removal of terminal galactose residues from IgG glycans significantly reduces 
complement-dependent cytotoxicity (CDC)63,64. IgGs containing high-mannose glycans and 
glycans with terminal GlcNAc residues (agalactosylated glycans) have been shown to bind to the 
mannose receptor (MR) which plays a potential role in antibody clearance65–68. 
Role of glycans in activation of complement pathways 
Banda et al69 have reported that the alternative complement pathway can also be initiated by IgG 
antibodies present in the form of immune complexes (and not just by the spontaneous hydrolysis 
of the complement component C3) and that this process is dependent on IgG N-glycans. The 
same study has also shown that agalactosylated IgG activates both the classical and alternative 
complement pathways more efficiently than the lectin pathway. 
Role of IgG glycans in the IgG-FcRn interaction 
The neonatal receptor (FcRn) transports IgG from mother to fetus and also, throughout life, 
regulates the serum half-life of IgG15. Although it was thought that the interaction between IgG 
and the neonatal Fc receptor (FcRn) is not influenced by Fc glycosylation, recent data suggest 
that glycans on IgG do affect the IgG-FcRn interaction70,71. 
Fab glycans 
There is emerging evidence that Fab glycosylation has a significant impact on the functional 
properties of IgG. Fab glycosylation can presumably affect antigen-binding affinity, antibody 
half-life, antibody aggregation and immune complex formation72. 
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1.4 Changes in IgG glycosylation have been observed in many diseases 
A great number of studies reported significant changes in the composition of the IgG glycome in 
different diseases. Over 30 years ago, Parekh et al8 reported that the IgG glycosylation profile is 
changed in patients with rheumatoid arthritis and since then lots of work has been done on IgG 
glycosylation in rheumatoid arthritis28,73–76. These subsequent studies confirmed and extended 
initial observations and also demonstrated that the glycosylation pattern of IgG which is 
associated with rheumatoid arthritis is detectable before the onset of the disease77. Moreover, 
following the discovery of the correlation between decreased galactosylation and occurrence of 
rheumatoid arthritis, changes in IgG glycosylation have been observed in numerous other 
inflammatory and autoimmune diseases including psoriatic arthritis78, systemic lupus 
erythematosus79,80, inflammatory bowel disease81,82, Hashimoto's thyroiditis83, Sjögren's 
syndrome73,84, Lambert-Eaton myasthenic syndrome and myasthenia gravis85. In addition, 
aberrant IgG glycosylation was also demonstrated in neurodegenerative diseases86–88, infectious 
diseases89–94, cancers95–106, periodontal disease107, small vessel vasculitis108 and in many other 
diseases. Furthermore, it was also reported that IgG glycosylation changes in pregnancy27,109, 
upon vaccination and depending on the type of vaccine used (different vaccines are needed for 
different pathogens)110–113, after anti-TNF therapy114, after treatment with different B cell 
stimulants (such as all-trans retinoic acid, CpG oligodeoxynucleotide, interleukin-21, etc.)115 and 
depending on hormonal status98,116. 
 
1.5 Aging 
Aging is most commonly described as a complex and continuous process characterized by the 
increasing accumulation of damage and changes with time that leads to progressive functional 
decline, increased susceptibility to disease and ultimately, death117,118. A large body of scientific 
literature exists on aging and many research efforts have been made in an attempt to unravel the 
underlying mechanism of aging. Multiple lines of evidence have been provided suggesting the 
existence of multiple mechanisms of aging. Recently, nine hallmarks of aging were proposed that 
characterize the process of aging and define the mechanisms that contribute to the aging 
process118. These hallmarks are: 1) Genomic instability (accumulation of DNA damage and 
disruption of nuclear architecture); 2) Telomere shortening; 3) Epigenetic alterations (alterations 
of histone modifications, DNA methylation, chromatin remodeling and transcriptional 
alterations); 4) Loss of proteostasis (decline in chaperons synthesis and activity of proteolytic 
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systems); 5) Deregulated nutrient sensing (deregulation of the nutrient sensing pathway: insulin 
and insulin growth factor 1 (IGF-1)-signaling, mammalian target of rapamycin (mTOR), 
adenosine monophosphate-activated protein kinase (AMPK) and sirtuins); 6) Mitochondrial 
disfunction (increase in reactive oxygen species (ROS) production, reduction in mitochondrial 
biogenesis and disruption of mitochondrial integrity); 7) Cellular senescence; 8) Stem cell 
exhaustions; 9) Altered intercellular communication (chronic low-grade inflammation  
(inflammaging)). Each of the proposed hallmarks fully or partly meets the following three criteria 
for designation as a hallmark of aging: 1) it should manifest during normal aging; 2) experimental 
aggravation should accelerate aging; 3) experimental amelioration should slow down normal 
aging and extend lifespan118. The hallmarks are interconnected, they co-exist and interact with 
each other during aging and together determine the aging phenotype118. 
The genetic contribution to variation in human lifespan has been estimated to range from 15 to 
30%, based on twin and population studies119. Environment and lifestyle also influence the aging 
process. It has been shown that various environmental factors and lifestyle choices, such as diet, 
physical activity, stress, smoking, radiation, air pollution and many others, can accelerate or delay 
the progression of aging120–125. 
 
1.6 Chronological and biological age 
It is known that all organ systems decline in functionality with age and that this results in age-
related changes in physical appearance, as well as in changes in physical and cognitive 
abilities124,126. Moreover,  the age-associated physiological deterioration is a major risk factor for 
many common diseases, such as Alzheimer’s disease, diabetes, heart disease, and cancer 127–129. 
The rates of occurrence of these and many other age-related diseases increase dramatically with 
age128. However, although all people age (i.e. experience age-related changes) they do not age at 
the same rate130–133. People of the same chronological age can vary greatly in physical 
appearance, disability, health status and can possess different risks for age-associated diseases, or 
in other words, people of the same chronological age can vary considerably in their biological 
age131,133–135. Chronological age is a measure of time that has passed since birth. On the other 
hand, biological age, which is a measure of the health status and overall physiological state of an 
individual, is determined by physiology rather than chronology131,134–136. The existence of large 
interindividual differences in the rate and extent of physiological decline associated with aging, as 
well as differences in susceptibility to different age-related diseases has led to a need for 
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biomarkers of aging that can be used to predict, monitor, and provide insight into age-related 
physiological decline and disease130–132,134,135,137,138. Such biomarkers could be also used to guide 
lifestyle changes (for individuals at high risk of age-associated morbidity and mortality) or early 
treatment of age-related diseases134. Furthermore, biomarkers of aging could serve to monitor and 
evaluate interventions that may potentially slow the progression of age-related physiological 
decline, prevent or delay the onset of age-related diseases and extend healthy lifespan132,134. 
Moreover, given the increase in the elderly population throughout the world and the 
accompanying rise of age-related diseases and their economic burden (i.e. increase in healthcare 
costs)139,140, the urgent need for effective biomarkers of aging has become even more evident131. 
 
1.7 Biomarkers of aging 
The American Federation for Aging Research has proposed the following criteria for a biomarker 
of aging: 1) it must predict rate of aging (i.e. it should tell us exactly where a person is in their 
total lifespan) and be a better predictor of lifespan than chronological age alone; 2) it must 
monitor a basic process that underlies the aging process, not the effects of disease; 3) it must be 
able to be tested repeatedly without harming the person (e.g. blood test or an imaging technique); 
4) it must be something that works in humans and in laboratory animals, such as mice (so that it 
can be tested in laboratory animals before being validated in humans)141,142. To date, a very large 
number of potential molecular and physiological biomarkers of aging have been proposed in the 
literature130–132,135,143. Among all candidate biomarkers of aging, telomere length and DNA 
methylation are probably the best studied. 
 
1.7.1 Telomere length 
Telomeres are DNA-protein complexes (tandem repeats of the TTAGGG sequence and 
associated protective proteins) located at the ends of chromosomes that protect the genomic DNA 
from degradation, unnecessary recombination and interchromosomal fusion during cell division. 
With each round of cell division, telomeres become shorter because telomerase, the enzyme 
responsible for maintaining telomere length, has very low or undetectable activity in many human 
cell types144,145. Both cross-sectional and longitudinal studies have shown that leukocyte telomere 
length decreases with age, but it appears that the correlation between telomere length and 
chronological age is rather weak with a correlation coefficient of only around -0.3146,147. There is 
high interindividual variability in telomere length at birth148 and among individuals of the same 
age149. Part of this variability is heritable149 and part is determined by environmental factors150,151. 
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Many, but not all, studies have demonstrated that the individuals with shorter leukocyte telomere 
lengths have a higher mortality rate145,147,152,153. Moreover, shorter telomeres have been associated 
with a variety of age-related conditions and diseases, including cardiovascular disease, 
Alzheimer’s disease, diabetes, various cancers, poor immune function and osteoporosis, although 
not all studies have confirmed these associations130,138,145,147,153,154. Also, telomere length has been 
inconsistently associated with measures of physical function, cognitive function and general 
health status152,153. Interindividual telomere length variability may partly explain such conflicting 
results152,155,156. Further, there is also evidence suggesting that telomere length and the rate of 
telomere shortening can reflect lifestyle habits/factors. It has been proposed that unhealthy 
lifestyle habits/factors such as smoking, lack of physical activity, obesity, stress, exposure to 
pollution, etc. can potentially increase the rate of telomere shortening, disease risk, and pace of 
aging. On the other hand, dietary restriction, appropriate diet and regular exercise can potentially 
reduce the rate of telomere shortening, disease risk, and pace of aging150,151,154,157. Mice have 
longer telomeres than humans and also higher telomerase activity in somatic cells, but the 
lifespan of mice is shorter than that of  humans152,153,158–160. In addition, it seems that mouse 
strains with longer telomeres do not live longer than mouse strains with shorter telomeres160. 
However, telomere shortening with age has been observed in mice118,152,160. Furthermore, it has 
been shown that knocking-out telomerase in mice leads to telomere shortening, but several 
generations of such mice appear to be phenotypically normal. Later generations of telomerase-
deficient mice show reduced lifespan and some signs of premature aging, including reduced stress 
response, increased genetic instability and reduced tissue regeneration152,153,160–162. Besides this, it 
has been shown that reactivation or overexpression of telomerase in mice can reverse or delay 
aging118,152,153,160. 
 
1.7.2 DNA methylation 
DNA methylation refers to the presence or absence of a methyl group (5-methylcytosine) at CpG 
dinucleotides. In the genome, CpG dinucleotides tend to come in clusters called CpG islands, 
which are mostly found in or near gene promoters (~5% of all CpGs in mammalian genomes). 
CpG islands are mainly unmethylated. However, the majority of CpG dinucleotides are dispersed 
throughout the genome and are predominately methylated163–165. It has been shown that DNA 
methylation levels of certain CpG sites in the human genome are highly correlated with 
chronological age131,163,164,166,167. These CpG sites either get hypermethylated or hypomethylated 
with age and when combined these sites can accurately predict chronological age, with a 
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coefficient of correlation of up to 0.97166,167. Such a biomarker of age is often called the 
“epigenetic clock/age” or “DNA methylation age”131,163,167,168. Moreover, it has been 
demonstrated that DNA methylation-based biomarkers can accurately predict age across different 
tissues167. Besides being able to accurately predict chronological age, DNA methylation has also 
been found to be a good predictor of biological age. Studies have linked DNA methylation age 
acceleration (residuals of the DNA methylation age estimate regressed on chronological age) 
and/or the difference between DNA methylation age and chronological age (Δage) to mortality, 
physical and cognitive (in)ability and age-related diseases such as cancers, Alzheimer’s disease 
and Parkinson's disease131,168–171.Very recently, a DNA methylation age predictor has been 
identified in mouse172. However, the molecular mechanism underlying age-related changes in 
DNA methylation and the role of these changes in aging remain to be elucidated131,163,164. 
It has also been reported that telomere length and DNA methylation age estimates do not 
correlate to each other and that they are independent predictors of chronological age. It is 
therefore likely that telomeres and DNA methylation employ different aging mechanisms and 
describe different parts of the aging process173,174. Given the existence of multiple mechanisms of 
aging and also the fact that all potential biomarkers of aging reported to date have some 
advantages and disadvantages, it has been proposed that a combination of different biomarkers of 
aging might measure biological age better than any individual marker134. 
 
1.8 Aging in mice 
Mice are the most commonly used animal model for studying different aspects of human biology 
and disease (about 61% of total animals used175) due to the their high level of genetic and 
physiological similarity to humans but also due to a number of other factors like low cost, 
relatively short lifespan, availability, genetic manipulability and the ability to control for 
environmental effects. The field of aging is not exception - the mouse has also been extensively 
used as an experimental animal in aging research. However, some aspects of aging are different 
between mice and humans. The average lifespan of laboratory mice is 1-3 years (depending on 
strain), whereas the average lifespan of humans is about 80 years (but this varies depending on 
the country)176. Several hypotheses have been proposed to explain the difference in lifespan 
between mice and humans, including differences in the mass-specific metabolic rate, production 
rate of reactive oxygen species (ROS), body size and DNA repair capacity177–180. As already 
mentioned earlier, mice have longer telomeres than humans and also have active telomerase 
enzyme in almost all their tissues159,181 but their lifespan is much shorter than that of humans, 
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implying that telomeres are not relevant to aging in mice. Although, there is also some evidence 
to suggest that telomeres may be relevant to aging in mice182 and also that long telomeres in mice 
potentially protect against age-dependent diseases such as cardiovascular disease183. Moreover, 
mice and humans differ in respect to age-related pathologies that they develop. For example, 
although quite common in elderly people, cardiovascular disease and Alzheimer’s disease are rare 
or nonexistent in old mice125. Additionally, in mice, mesenchymal and hematopoietic cancers 
prevail, whereas humans predominantly suffer from epithelial cancers177. Many mouse models of 
aging have been developed, including premature aging mouse models, mouse models of delayed 
aging and mouse models of human premature aging syndromes (i.e. Werner syndrome (WS) and 
trichothiodystrophy (TTD))125,159. Although mouse models have proven useful for studying aging, 
these models also have some limitations. First, mouse models of accelerated aging and premature 
aging syndromes display only a few characteristics of premature aging125.  Second, most aging 
studies in mouse models use inbred strains that might not be representative of a genetically 
diverse aging human population159,184. Finally, the genetic background of the strain used could 
affect the results of aging studies. For example, many inbred strains exhibit some strain-specific 
pathologies which may interfere with the studied aging phenotype184. 
 
1.9 Changes in IgG glycosylation with age: Studies in human populations 
Exactly three decades ago, in 1988, Parekh et al.185 reported that IgG glycosylation changes with 
age. By examining IgG glycosylation in a population of 151 healthy individuals of both sexes 
ranging in age from 1 to 70 years, they observed a decrease in agalactosylated (lacking galactose) 
glycans until the age of approximately 25 years, and afterwards an increase in the same group of 
glycans with age, while age-related changes of digalactosylated glycans were inverse to those 
observed for agalactosylated glycans. They also noted that the level of monogalactosylated 
glycans remained constant with age. However, they found no significant differences between the 
sexes in the galactosylation of IgG. Studies following this initial observation further confirmed 
the reported association between a change in IgG galactosylation and age, but some new links 
between IgG glycans and age were also established. In a subsequent study on 112 healthy 
individuals of both sexes (20-70 years old) the age–related increase in agalactosylated IgG 
gylcans was confirmed for both sexes186. In addition, the study also reported that male individuals 
showed slightly higher levels of IgG agalactosylation than females of the same age. In a study 
published several years later, in 1997187, IgG glycosylation was analyzed in 176 female and 227 
male individuals (403 individuals in total) varying in age from 0 to 85 years. It was found that not 
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only galactosylated glycans but also bisecting GlcNAc containing glycans display age-dependent 
changes; both agalactosylated glycans and bisecting GlcNAc-containing glycans were shown to 
increase with increasing age. It was also observed that the level of agalactosylated glycans 
correlated with age better in females (rs=0.666) than in males (rs=0.327). Moreover, a difference 
in the level of agalactosylated IgG glycans between males and females in their twenties was 
reported; the level of agalactosylated glycans was found to be lower in females than in males 
(similar to what had been reported previously by Tsuchiya et al.186). A year later, Shikata et al.188 
published a study that investigated the glycosylation of IgG in a small cohort consisting of 43 
female and 37 male healthy individuals ranging in age from 18 to 73 years. In a slight contrast to 
previous studies, a significant age-dependant increase in agalactosylated glycans and 
corresponding decrease in digalactosylated glycans were observed in females only. This 
inconsistency with previous studies could have arisen due to the small sample size of the study 
(only 37 male individuals) and consequent low statistical power. In female individuals a decrease 
in the level of monosialylated glycans with age was also reported. However, the level of IgG 
glycans with bisecting GlcNAc was found to increase with age in both sexes and this finding was 
consistent with that of a previous study by Yamada et al.187, while, on the other hand, the levels of 
disialylated, monogalactosylated, or fucosylated IgG glycans did not change with age neither in 
males or females. In a more recent study, the age-dependent changes in IgG glycans were 
evaluated in a small sample of 62 individuals of both sexes aged between 22 and 79 years189. 
Consistent with earlier findings, results from this study demonstrated that the abundance of 
agalactosylated glycans increased with increasing age, while the abundance of digalactosylated 
glycans, as well as the abundance of monosialylated digalactosylated glycans, decreased with 
age. Additionally, in accordance with previous studies, the level of bisecting GlcNAc increased 
with age. 
 
Furthermore, four studies with large simple sizes have explored the association between IgG 
glycans and age and they used different high-throughput methods to analyse IgG glycosylation. In 
the first of these studies published in 2010190, the glycosylation of IgG was analysed in 1287 
offspring of long-lived siblings and in 680 partners of the offspring (age 30-79 years) from the 
Leiden Longevity Study. Six different IgG glycans were quantified by using MALDI-TOF 
(Matrix-Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry analysis, which 
included two agalactosylated core fucosylated biantennary glycans (with and without bisecting 
GlcNAc), two monogalactosylated core fucosylated biantennary glycans (with and without 
bisecting GlcNAc) and two digalactosylated core fucosylated biantennary glycans (with and 
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without bisecting GlcNAc), and the relationship between each of these six glycans and age was 
explored. This study confirmed the previously reported age-related increase in agalactosylated 
glycan structures (with and without bisecting GlcNAc) and decrease in digalactosylated glycan 
structures (with and without bisecting GlcNAc). In addition, sex-related differences were 
observed at ages below 60 years. The level of agalactosylated glycans was lower in younger 
females (ages <60 years) than in males, but females also showed a more pronounced increase in 
agalactosylated glycans with increasing age, resulting in similar galactosylation for both sexes 
above the age of 60. It was also found that the ratio of presence to absence of bisecting GlcNAc 
in digalactosylated structures tended to increase with increasing age. Interestingly, in the same 
study, the authors also observed that at ages below 60, the offspring of nonagenarian siblings 
(who were assumed to have a higher susceptibility to become long-lived) had a lower level of 
agalactosylated core fucosylated biantennary glycan with a bisecting GlcNAc when compared to 
the partners of the offspring (who represented the general population and served as control 
subjects), indicating the potential of bisecting GlcNAc-containing agalactosylated glycan from 
human IgG as an early biomarker of human longevity. Moreover, given that the offspring were 
previously observed to be healthier than their partners (they showed lower prevalence of 
myocardial infarction, hypertension and diabetes mellitus)191, the authors speculated about the 
possibility that the lower level of agalactosylated glycan with bisecting GlcNAc (compared to the 
average level of the same glycans observed in the general population) could be an indicator of 
better health status, thus raising the interesting possibility that this IgG glycans could be used as a 
biomarker of healthy aging. In the second of four large-scale studies published in 201125, the 
association of IgG glycosylation and age was investigated in a total of 2298 individuals of both 
sexes (age 18–100 years) from three isolated populations (from the Croatian island of Vis, the 
Croatian island of Korčula and the Northern Scottish Orkney Islands) using hydrophilic 
interaction liquid chromatography (HILIC). A strong association between the level of IgG 
galactosylation and age was observed (age explained 35% of the variance of agalactosylated 
glycans). In addition, an increase in bisecting GlcNAc content and a decrease in sialylation of 
IgG glycans were observed with increasing age, while core fucosylation of IgG did not change 
with age. However, this study did not examine age-related changes in IgG glycosylation in a sex-
specific manner. In the third large-scale study published in 201298, the age-related changes in IgG 
glycosylaton were analysed in a cohort of 735 healthy Chinese individuals of both sexes (6-70 
years old) using MALDI-FTICR (Matrix-Assisted Laser Desorption Ionization-Fourier-
Transform Ion Cyclotron Resonance) mass spectrometry analysis. Fourteen individual IgG 
glycans and seven IgG glycosylation features (i.e. galactosylation, agalactosylation, 
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monogalactosylation, digalactosylation, bisecting GlcNAc, afucosylation and sialylation) were 
measured. Although many findings of this study were in accordance with previous studies (i.e. 
increase in agalactosylated and decrease in digalactosylated glycans with increasing age), there 
were also some new observations, especially those related to sex-specific differences in the 
pattern of age-related changes in IgG glycosylation, which had not been reported previously. It 
was found that in males the level of agalactosylated glycans began to increase in twenties, 
whereas in females the level of agalactosylated glycans began to increase after midlife. In 
addition, at ages around the twenties and midlife females exhibited a lower level of 
agalactosylated glycans and a higher level of galactosylated glycans than males, while around the 
age of 70 years the situation was reversed (i.e. levels of galactosylated glycans were lower and 
levels of agalactosylated glycans were higher in females than in males). Interestingly, females 
showed more dramatic changes in glycosylation during lifetime than males, which were 
especially visible between the ages of 18 to 24 and 43 to 48 years, the two age ranges which 
coincide with the end of puberty and the onset of menopause, respectively. In the fourth study 
published in 2013192, the glycosylation of IgG was investigated by MALDI-TOF mass 
spectrometry in 1709 individuals of both sexes (age 18-98 years) from the Croatian island of Vis 
and Korčula (these two population-based cohorts were also used in the large-scale study 
published in 201125). Changes in levels of individual IgG glycans as a function of age were not 
explored; rather, this study focused on changes in four IgG glycosylation features, including 
sialylation, galactosylation, core fucosylation and the occurrence of bisecting GlcNAc, with 
respect to age. This study corroborated and extended the findings from the large-scale study 
published in 201298. The main findings of this study were that the age-related glycosylation 
changes in all examined glycosylation features were more pronounced in younger individuals 
(<57 years) than in older individuals (>57 years) and in females than in males. More specifically, 
in agreement with previous studies98, galactosylation and sialylation decreased with increasing 
age in both sexes and the most prominent decrease in the levels of both galactosylation and 
sialylation in females was observed around the age of 45 to 60 years, when females usually enter 
menopause. Furthermore, females showed higher levels of galactosylation and sialylation at 
younger age while males showed slightly higher levels at older age. The incidence of bisecting 
GlcNAc was found to increase with age but, interestingly, reached a plateau at older age. 
Additionally, the level of IgG core fucosylation decreased very slightly with increasing age but 
such association between core fucosylation and age was observed only in younger individuals. No 
sex differences were found for the bisecting GlcNAc and core fucosylation. 
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Very few studies have examined age-dependent changes in IgG glycosylation in children and 
adolescents, mainly because of difficulties in recruiting sufficient numbers of children and 
adolescents, and especially healthy children and adolescents. As already mentioned above, the 
study by Parekh et al.185 was the first to examine changes in IgG glycosylation with age in a 
cohort that consisted of both children and adults. The study found differences in the direction of 
age-related changes in IgG glycans between children and adults. In children agalactosylated 
glycans decreased with age while digalactosylated glycans increased with age and the opposite 
effect was observed in adults (i.e. agalactosylated glycans increased with age while 
digalactosylated glycans decreased with age). Successively, in a study on 164 healthy children 
and adolescents between 6 and 18 years of age (96 girls and 68 boys with a median age of 13 
years), a decrease in the level of agalactosylated and core-fucosylated IgG glycans and an 
increase in the level of digalactosylated IgG glycans with age was reported193, but only in girls, 
thus partially confirming the initial observation by Parekh et al.185. In boys, an increase in the 
incidence of bisecting GlcNAc in sialylated core-fucosylated structures with age was observed. In 
addition, this study revealed numerous differences in IgG glycans between girls and boys, 
especially at the onset of puberty. Another study on 609 children between 3 and 11 years of age 
(288 girls and 321 boys with a median age of 8 years) confirmed the previously reported age-
dependent decrease in agalactosylated and increase in digalactosylated glycans, but also reported 
an age-dependent increase in monogalactosylated glycans and in glycans containing bisecting 
GlcNAc and a decrease in the level of core fucosylation and sialylation194. However, in 
disagreement with previous studies which demonstrated a tendency toward an age-dependent 
increase of galactosylation levels in children, one study of children and adolescents ranging in 
age from birth to 17 years (n=90, 44 girls and 46 boys) showed that galactosylation remained 
relatively constant throughout childhood and adolescence195. The same study also observed a 
decrease in fucosylation and sialylation and an increase in bisection between birth and 17 years of 
age, which were in accordance with the findings of previous studies. 
 
A number of studies have investigated changes in the abundance of different glycan structures 
with age in total plasma or serum proteins instead of on individual proteins like IgG31,32,196–200. 
Two such studies from the same group found that individuals with premature aging syndromes 
(i.e. Werner syndrome and Cockayne syndrome) exhibited different a glycosylation pattern 
compared with that observed in age-matched controls, but which was rather comparable with the 
glycosylation pattern observed in very elderly (90 years and above)199,200. In addition, the same 
group of investigators reported that patients with dementia displayed the same glycosylation 
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features as individuals older than their respective controls, implying that glycans could be better 
than chronological age for estimating the biological age of an individual, and therefore could be 
used as an aging biomarker. Another study which analyzed glycans from total plasma proteins 
reported that increased body fat and blood pressure were associated with an increase in 
agalactosylated and a decrease in digalactosylated glycans and the same glycans were also shown 
to change with age; agalactosylated glycans increased and digalactosylated decreased with age31. 
Furthermore, in a more recent study which analyzed glycans derived from total plasma proteins, 
two glycan features were found to be associated with longevity, some indicators of overall health 
status (such as BMI, cholesterol and CRP) and also with incidence of myocardial infarction198. 
Therefore, studies on glycans from total plasma proteins have not only demonstrated that glycans 
undergo significant changes with age but also according to these studies it seems that based on 
glycans it is possible to distinguish between healthy and unhealthy aging. However, given that 
these observations were made on total plasma glycans which actually represent the sum of 
glycans which originate from many different plasma proteins, it is not clear whether these 
observations can also be applicable to IgG glycans.  
 
Furthermore, changes in IgG glycans have been observed in many age-related diseases, including 
type 2 diabetes201, Alzheimer’s disease86 and several types of cancer including lung97, 
colorectal105 and prostate cancer100. In general, when compared to healthy individuals of the same 
age, patients with age-related disease showed increased level of agalactosylated glycans and 
decreased level of digalactosylated glycans. The same pattern of change in IgG glycans, as 
observed in patients suffering from age-related diseases, has been reported previously to also 
occur with increasing age. 
 
1.10 Changes in IgG glycosylation with age: Studies in mice 
Only a few studies exist in the literature that have investigated changes in IgG glycosylation with 
age in mice. In a study conducted by Bodman et al.202 seven different mouse strains were assessed 
at six distinct ages (2, 3, 4, 5, 6 and 8 months) for age-related changes in agalactosylated IgG 
glycans. An increase in the level of agalactosylated IgG glycans with age in six out of seven 
mouse strains was found.  Another study examined age-related changes in glycosylation of total 
serum proteins in C57BL/6 mice aged between 3 and 25 months203. Levels of three glycans in 
total serum and in immunoglobulin (Ig)-depleted serum were found to change with increasing 
age: levels of agalactosylated and digalactosylated core-fucosylated bianatennary glycans 
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increased with age, while level of digalactosylated bianatenary glycans decreased. However, this 
same study did not examine age-related changes in glycosylation of the immunoglobulin (Ig) 
fraction. 
 
1.11 Research problem and scope of the thesis 
Based on the previous studies, indications exist that glycosylation of IgG changes with age and 
that IgG glycans could be used to evaluate overall age-related health status. However, previous 
studies that investigated glycosylation changes with age were characterized by several important 
limitations. First, most of the studies had relatively small sample sizes, meaning that the obtained 
results may not reflect a true effect204,205. It is only relatively recently that the high-throughput 
methods for analysis of IgG glycosylation have been developed that enable analysis of large 
number of samples in a short period of time. These methods include mass spectrometry (MS), 
capillary electrophoresis (CE) and liquid chromatography (LC)206. Second, many of the previous 
studies were performed on total plasma glycans (i.e. glycans that originate from all plasma 
proteins and not only from IgG), thus, in addition to changes in glycosylation of only one, some 
or all of the plasma proteins, the observed differences reflected changes in the abundance of 
individual plasma proteins. Additionally, there were also studies that did not cover the entire adult 
lifespan and those that did not examine the factor of sex in the patterns of changes in IgG 
glycosylation with age. Furthermore, some previous studies investigated the age-related changes 
of only a few, most highly abundant, individual IgG glycans while other studies focused only on 
changes in specific glycosylation features shared by many individual IgG glycans such as 
galactosylation, sialylation, core fucosylation, etc. There were also inconsistencies between 
studies and also some isolated observations reported in only one of the studies but not in others. 
 
In this thesis and the presented scientific papers we sought to perform a detailed analysis of 
changes in IgG glycosylation with age on a large number of individuals, over the entire adult life 
span and in several different populations. We also investigated changes in IgG glycoslation with 
age on an animal model. Finally, we aimed to explore the potential of glycans to be used as 
biomarkers of chronological and biological age.
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5. GENERAL DISCUSSION 
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Glycosylation significantly affects structural and functional properties of immunoglobulin G 
(IgG), with multiple effects on the immune system207,208. In addition, numerous studies reported 
significant changes in the composition of the IgG glycome in different diseases7,208. These and 
other findings and observations in the field have pointed out that examination of glycosylation is 
of great interest in understanding the biology of IgG molecule, regulation of immune response 
and in understanding how changes in IgG glycosylation are linked to other processes in body in 
both physiological and pathological states. Characterization of IgG glycosylation in individuals 
from the general population is very useful as it forms a basis for all future studies on IgG 
glycosylation. Information about the variability of IgG glycosylation in the general population, 
and its dependency on age and sex is highly desirable and even indispensable. 
We analyzed IgG glycoslyation in almost 6000 individuals from five different populations (four 
European populations and a Han Chinese population) with a very broad range of ages (from 16 to 
100 years) which allowed us to gain a better understanding of the relationship between 
glycosylation of IgG and age. The levels of nearly all IgG glycans were found to significantly 
change with age. With increasing age the following changes were most pronounced:  1) an 
increase in levels of agalactosylated core-fucosylated biantennary glycans (with and without 
bisecting GlcNAc), 2) a decrease in levels of digalactosylated core-fucosylated biantennary 
glycans (with and without bisecting GlcNAc), and 3) a decrease in the level of monosialylated 
digalactosylated core-fucosylated biantennary glycan without bisecting GlcNAc. These 
observations can be summarized as an increase in levels of agalactosylation and a decrease in 
levels of digalactosylation and sialylation with increasing age and they are consistent with 
previous findings185,187. Interestingly, although slight differences in age-related IgG glycosylation 
changes between different populations were observed, overall patterns of changes in IgG glycans 
with age were very similar among all examined populations. This may imply the existence of a 
universal principle of changes in IgG glycosylation with age, regardless of population. In 
addition, our findings demonstrate that age and sex interact, so that glycosylation changes with 
age are more prominent in females than in males. In particular, we found that, in women, the 
most dramatic change in IgG glycosylation occurred between the ages of 40 and 60 years, which 
coincides with the menopause transition, a period characterized by hormonal changes. 
Interestingly, not only do hormones modulate IgG glycosylation209, but sex differences in 
hormonal status have been proposed as a possible explanation for sex differences in lifespan210. 
This indicates that the relationship between age, sex, hormonal status and changes in IgG 
glycosylation is quite complex as these factors are obviously not independent of each other. 
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The exact molecular mechanisms that underlie age-related changes in IgG glycosylation are not 
currently known. However, the consistency of changes between different populations, points to a 
tight regulation of age-related changes in IgG glycosylation. Several mechanisms have been 
proposed that may lead to age-related changes in IgG glycosylation. It has been suggested that a 
decrease in IgG galactosylation (and an increase in IgG agalactosylation) with age may be 
explained by a decrease in the expression and/or activity of beta-1,4-galactosyltransferase 
(B4GALT) enzyme that adds galactose to glycans185,200. However, the expression level and/or 
activity of galactosyltransferase in B lymphocytes have not been examined in the general 
population across a wide age range and correlated with glycan levels. Recently, one study 
measured the activity of galactosyltransferase in the plasma of 125 individuals ranging in age 
from 5 to 105 years211 and reported an increase in plasmatic galactosyltransferase activity with 
age but the level of enzyme activity did not correlate positively with the level of IgG 
galactosylation. The expression (mRNA and protein level) and enzyme activity of  
galactosyltransferase have been examined in B lymphocytes of rheumatoid arthritis patients and 
healthy controls212–216, cell culture systems217 and in mouse models214. These studies yielded 
conflicting results, with some studies finding a negative relationship between the expression 
and/or activity of galactosyltransferase and levels of agalactosylated glycans216,217, while others 
found no relationships212–215. Furthermore, it has been suggested that the beta-galactosidase 
enzyme, that removes galactose from glycans, may also be responsible for age-related changes in 
IgG glycosylation196,200. It has also been proposed that age-related changes in IgG glycosylation 
might result from expansion of specific clones of B lymphocytes185,218. 
It is still unknown what purpose these age-related changes in IgG glycosylation serve. 
Agalactosylated glycans enable IgG to activate pro-inflammatory effector pathways through 
interaction with the mannose binding lecting (MBL)61 and Fcγ receptors62. On the other hand, 
galactosylated glycans enable IgG to exert anti-inflammatory activity through promotion of 
association between FcγRIIB and Dectin-160. This suggests that IgG glycosylation changes that 
occur with aging (i.e. an increase in agalactosylated glycans and corresponding decrease in 
digalactosylated glycans) would promote inflammation. A low-grade systemic chronic 
inflammatory status, called “inflammagingˮ, has been recognized as a hallmark of aging and is 
characterized by increased levels of pro-inflammatory molecules118,219. This age-related increase 
in pro-inflammatory status is suggested to be driven by lifelong antigenic load (e.g. microbial 
infections, damaged macromolecules and cells, changes in gut microbiota), age-related 
deregulation of the immune system (immunosenescence) and by numerous other factors such as 
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production of reactive oxygen species (ROS) and accumulation of senescent cells121,220–222. 
Chronic inflammation can contribute to the aging phenotype through promotion of tissue 
damage220,221 and is considered to be implicated in many age-related diseases121,221. Thus, age-
related changes in IgG glycosylation may represent an important contributor to the initiation 
and/or maintenance of chronic inflammation associated with aging, as suggested by Dall’Olio et 
al.223. However, although the evidence suggests the existence of a relationship between 
glycosylation changes, chronic inflammation and aging222,223, the direction of a cause-and-effect 
relationship remains unclear. It is very likely that there is no simple cause-and-effect relationship, 
rather, that there is a complex interplay between all these factors. 
The ability to accurately predict chronological age is very useful, especially in fields such as 
forensics. Our results demonstrate that IgG glycans are able to predict chronological age with 
correlation coefficients between the age predicted by IgG glycans and the chronological age 
ranging from 0.56 and 0.76 and an error of 9.7 years or higher depending on the population and 
number of glycans included in the prediction model. Although the precision of chronological age 
predictions based on glycans is rather moderate, and surely not precise enough for forensic 
purposes, it appears that glycans are more precise in the estimation of chronological age than 
telomere length which demonstrates correlation coefficient of around -0.3147. On the other hand, 
DNA methylation is probably the most accurate known predictor of chronological age with 
correlations between chronological age and predicted age higher than 0.9 and reported errors 
lower than 5 years166,167,224. 
Biological age often differs from chronological age. It is known that individuals of the same 
chronological age vary in their health and physiological status. We have shown that the difference 
between the age predicted by IgG glycans and the true chronological age (i.e. according to their 
IgG glycans some individuals were predicted to be younger or older than their chronological age 
and also, some individuals showed larger deviation from chronological age than others) can, at 
least partly, be attributed to differences in biochemical and physiological parameters (e.g. lung 
function parameters, blood pressure, BMI, triglycerides and lipoproteins). Therefore, it appears 
that the age that is estimated based on IgG glycans to some extent reflects an individual's general 
health status. Future studies, in particular longitudinal studies, are needed to confirm the potential 
of glycans to be used as a biomarker of biological age. In particular, studies should determine 
whether changes in IgG glycans are modifiable (i.e. can they be slowed or reversed by 
interventions such as dietary changes or physical exercise), and also whether the rate of change in 
IgG glycans could be used to monitor health status and to predict age-related diseases. 
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Mice are the most commonly used animal model for studying different aspects of human biology, 
including protein glycosylation. In this thesis we have also examined IgG glycosylation in 589 
mice from the Collaborative Cross (CC) cohort. The CC mouse population is derived from eight 
founder strains (five classical inbred strains and three wild-derived strains) and closely resembles 
genetic and phenotypic variability observed in human populations225,226. By analyzing IgG 
glycosylation in 95 different CC strains ranging in age from 20 to 80 weeks (most of the studied 
mice were in this age range) we found that the level of only one mouse IgG glycan changed with 
age. Interestingly, this glycan contains alpha-1,3-galactose that is not present in human IgG. To 
the best of our knowledge, only one prior study202 has investigated changes in IgG glycosylation 
with age in mice. The study analyzed levels of agalactosylated IgG glycans in seven strains of 
mice ranging in age from 2 to 8 months and it reported that levels of agalactosylated glycans (in 
six out of seven strains of mice) increased with age, thus confirming observations from human 
studies. On the contrary, we did not find a strong general trend toward a change in the level of 
agalactosylated glycans with age in the CC strains. This inconsistency may be due to: 1) 
differences in the age range that was covered (from 2 to 8 months in the study by Bodman et al. 
and from 20 to 80 weeks (which corresponds to approximately 5 to 20 months) in our study, 
and/or 2) possible differences in the antigenic and physical environmental conditions (for 
example, it is not clear whether in the study by Bodman et al.202 mice were kept in a specific 
pathogen-free environment, as were mice in our study). If the latter is true, then this would 
strongly support the “inflammaging hypothesisˮ which attributes to lifelong antigenic load the 
continuous increase of inflammation with age and consequential tissue damage that leads to 
health deterioration220,223. Future studies could explore the effects of antigenic challenge and/or 
different environmental factors on changes in IgG glycosylation during the lifetime of the mice. 
In the end, it is worth discussing whether IgG glycans fulfill the aging biomarker criteria 
suggested by the American Federation for Aging Research141,142. The first criterion has been 
defined as follows: It must predict rate of aging and be a better predictor of lifespan than 
chronological age alone. Given our observation that levels of IgG glycans exhibit strong 
correlations with physiological parameters used in the assessment of the individual’s health status 
and that IgG glycan levels are associated with mortality (our unpublished data), it is highly 
probable that IgG glycans meet the first criterion for biomarkers of aging. The second criterion 
has been defined as follows: It must monitor a basic process that underlies the aging process. 
Given our observation that individuals from different populations follow the same pattern of 
change in IgG glycosylation through lifetime and the possible role of IgG glycans in the chronic 
Jasminka Krištić - Changes of immunoglobulin G glycosylation with age 
 
60 
 
inflammation associated with aging-“inflammagingˮ, it is highly probable that IgG glycans also 
meet the second criterion for biomarkers of aging. The third criterion has been defined as follows: 
It must be able to be tested repeatedly without harming the person. IgG glycans are commonly 
analyzed in plasma or serum samples, thus, as glycan testing is minimally invasive, IgG glycans 
meet the third criterion for biomarkers of aging. The fourth criterion has been defined as follows: 
It must be something that works in humans and in laboratory animals. Since, as described in the 
previous paragraph, the only two studies (the study by Bodman et al.202 and our study) that have 
examined changes in IgG glycosylation with age to date have reported confilicting results 
regarding whether or not the levels of agalactosylated glycans change with age, future studies are 
necessary for addressing the fourth criterion. Taken together, it seems that IgG glycans have great 
potential as biomarkers of aging, either individually or in combination with other biomarkers of 
aging. 
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6. CONCLUSIONS 
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This thesis provides detailed information on the changes in IgG glycosylation through lifetime. 
By examining IgG glycosylation in 5818 individuals from five different populations (four 
European populations and a Han Chinese population) with a very broad range of ages (from 16 to 
100 years) we found that: 
• The levels of all IgG glycans showed a significant association with age. The strongest 
association with age was observed in the level of galactosylation. IgG glycans that lack 
galactose (agalactosylated glycans) increased with age, whereas IgG glycans that contain 
two galactoses (digalactosylated glycans) decreased with age. Among other IgG glycans, 
the level of monosialylated digalactosylated core-fucosylated biantennary glycan also 
showed a strong association with age and its level decreased with age. These findings 
suggest that age-related changes in IgG glycosylation would increase the pro-
inflammatory effector function of immunoglobulin G. 
 
• All examined populations exhibited similar patterns of changes in IgG glycosylation with 
age. 
 
• Men and women showed differences in the patterns of age-related changes in IgG 
glycosylation. Women exhibited more pronounced changes in IgG glycosylation with age 
than males, and especially between the ages of 40 and 60 years, an age range that 
coincides with menopause transition. 
 
• The combination of several IgG glycans was able to explain from 30 to 58% of the 
variation in chronological age, depending on the population and number of IgG glycans 
included in the model. After accounting for chronological age, the remaining variation in 
IgG glycans was shown to be associated with differences in physiological parameters 
associated with biological age. Therefore, IgG glycans have the potential to be used as a 
biomarker of chronological and biological ages. 
 
By examining changes in IgG glycosylation with age in nearly 600 mice belonging to 95 different 
Collaborative Cross strains and ranging in age from 20 to 80 weeks we found that only the level 
of IgG glycan containing alpha-1,3-galactose showed a significant association with age. 
Agalactosylated glycans did not show a general tendency to increase with age in mice. 
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APPENDIX 1: Comparison of trends of change in the level of agalactosylated glycan 
GP4 with age among different strains of mice. 
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APPENDIX 2: Association between glycan traits and mouse age. 
 
< 80 weeks old 
Glycan effect DF SE p.val p.adj 95% confidence intervals 
GP17b -0,01385 417 0,002394 1,42E-08 8,20E-08 (-0.0186 - -0.0091) 
GP6 -0,01339 417 0,002317 1,49E-08 8,20E-08 (-0.0179 - -0.0088) 
GP17a -0,00712 417 0,00222 0,001444 0,005294 (-0.0115 - -0.0028) 
GP8 0,003495 417 0,002138 0,102763 0,282597 (-0.0007 - 0.0077) 
GP20 -0,00288 417 0,002141 0,17892 0,360517 (-0.0071 - 0.0013) 
GP9 -0,00364 417 0,002814 0,196646 0,360517 (-0.0092 - 0.0019) 
GP14 0,001823 417 0,001852 0,325399 0,511341 (-0.0018 - 0.0055) 
GP23 0,002062 417 0,002877 0,473861 0,651559 (-0.0036 - 0.0077) 
GP1 0,001146 417 0,00231 0,619889 0,757642 (-0.0034 - 0.0057) 
GP4 0,000391 417 0,001909 0,837958 0,858208 (-0.0034 - 0.0041) 
GP25 0,000551 417 0,003084 0,858208 0,858208 (-0.0055 - 0.0066) 
Sample size is n=494 biologically independent mice (75 CC strains) 
 ≥20  to  <80 weeks old 
Glycan effect DF SE p.val p.adj 95% confidence intervals 
GP23 0,012612 386 0,003452 2,94E-04 3,23E-03 (0.0058 - 0.0194) 
GP17b -0,00608 386 0,003031 4,56E-02 2,45E-01 (-0.0120 - -0.0001) 
GP6 -0,00555 386 0,003019 6,68E-02 2,45E-01 (-0.0115 - 0.0004) 
GP17a -0,00458 386 0,002751 9,65E-02 2,51E-01 (-0.0100 - 0.0008) 
GP25 0,006036 386 0,00385 1,18E-01 2,51E-01 (-0.0015 - 0.0136) 
GP14 0,003476 386 0,002332 1,37E-01 2,51E-01 (-0.0011 - 0.0081) 
GP8 -0,00335 386 0,002732 2,21E-01 3,47E-01 (-0.0087 - 0.0020) 
GP4 -0,00145 386 0,002341 5,37E-01 5,72E-01 (-0.0060 - 0.0032) 
GP1 0,001683 386 0,002856 5,56E-01 5,72E-01 (-0.0039 - 0.0073) 
GP9 0,002076 386 0,00362 5,67E-01 5,72E-01 (-0.0050 - 0.0092) 
GP20 0,001458 386 0,002576 5,72E-01 5,72E-01 (-0.0036 - 0.0065) 
Sample size is n=461 biologically independent mice (73 CC strains) 
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